IGFs and IGFBPs in health and disease

This project is supervised by Jaap van Doorn (see link at bottom of page)

Recent publications:

  • Rikken, B., J. van Doorn, A. Ringeling, J. L. Van den Brande, G. Massa and J.-M. Wit. Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm. Res. 50:166-176 (1998).
  • van Doorn, J., A. M. Ringeling, S. S. Shmueli, M. C. Kuijpers, A. C. S. Hokken-Koelega, S. C. van Buul-Offers, M. Jansen. Circulating levels of human-insulin-like growth factor binding protein-6 (IGFBP-6) in health and disease as determined by radioimmunoassay. Clin. Endocrinol. 50:601-609 (1999).
  • Yu, H., J. Mistry, M. J. Nicar, M. J. Khosravi, A. Diamandis, J. van Doorn, A. Juul. Insulin-like growth factors (IGF-I, Free IGF-I, and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J. Clin. Lab. Anal. 13:166-172 (1999).
  • van Doorn, J., A.J.F.H. Cornelissen, S.C. van Buul-Offers. Plasma levels of insulin-like growth factor binding protein-4 (IGFBP-4) under normal and pathological conditions. Clin. Endocrinol. 54: 655-664 (2001).
  • van Doorn, J., A.M. Ringeling, B. Rikken, S.C. van Buul-Offers. Plasma levels of insulin-like binding protein-2 in prepubertal short children and its diagnostic value in the evaluation of growth hormone deficiency. Horm. Res. 55:147-154 (2001).
  • Gulmans,V., J. van der Laag, D. Wattimena, J. van Doorn, D. Oostveen, R. Berger, K. de Meer. Insulin-like growth factors and leucine kinetics during exercise training in children with cystic fibrosis. J. Pediatr. Gastoenterol. Nutr. 32:76-81 (2001).
  • Wit, J.M., V.J. Langenhorst, M. Jansen, W. Oostdijk, J. van Doorn. Dehydroepiandrosterone-sulphate treatment for atrichia pubis. Horm. Res. 56:134-139 (2001).
  • Kamp,G.A., D.M. Ouwens, C.M. Hoogerbrugge, A.H. Zwinderman, J.A. Maassen, J.M. Wit. Skin fibroblasts of children with idiopathic short stature show an increased mitogenic response to IGF-I and secrete more IGFBP-3. Clin. Endocrinol. 56:439-447 (2002).
  • Kamp, G.A., A.H. Zwinderman, J. van Doorn, W. Hackeng, M. Frolich, E. Schonau, J.M. Wit. Biochemical markers of growth hormone (GH) sensitivity in children with idiopathic short stature: individual capacity of IGF-I generation after high-dose GH treatment determines the growth response to GH. Clin. Endocrinol. 57:315-325 (2002).
  • Boersma, B., R.H. Houwen, W.F. Blum, J. van Doorn, J.M. Wit. Catch-up growth and endocrine changes in childhood celiac disease. Endocrine changes during catch-up growth. Horm. Res. 58 (suppl. 1):57-65 (2002).
  • Rooman, R.P.A., L. Op De Beeck, M. Martin, J. van Doorn, S. Mohan, M.V.L. Du Caju. IGF-I, IGF-II, ‘free’IGF-I and IGF-binding proteins-2 to –6 during high-dose oestrogen treatment in constitutionally tall girls. Eur. J. Endocrinol. 146:823-829 (2002).
  • de Groof, F., K.F.M. Joosten, J.A.M.J.L. Janssen, E.D. de Kleijn, J.A. Hazelzet, W.C.J. Hop, P. Uitterlinden, J. van Doorn, A.C.S. Hokken-Koelega. Acute stresse response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. J. Clin. Endocrinol. Metab.87:3118-3124 (2002).
  • van Doorn, J., C.M. Hoogerbrugge, M. Jansen, S.C. van Buul-Offers. Insuline-achtige groeifactor (IGF)-II: biologische eigenschappen en de klinische relevantie. Ned. Tijdschr. Klin. Chemie 27:163-169 (2002).
  • Twickler, T.B., M.G.M. de Sain-van der Velden, J. van Doorn, T.W. van Haeften. Insulin-like growth factor-I genotype and birthweight. Lancet 360:946 (2002).
  • De Boer L., C.M. Hoogerbrugge, J. van Doorn, S.C. van Buul-Offers, M. Karperien, J.M. Wit. Plasma insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), acid-labile subunit (ALS) and IGFBP-3 proteolysis in individuals with clinical characteristics of Sotos syndrome. J. Ped. Endocrinol. Metabol. 17:615-627 (2004).
  • Van Doorn, J., H.J. Gilhuis, J.G. Koster, P. Wesseling, R.E. Reddingius, M.G. Gresnigt, R.J. Bloemen, G.N.P. van Muijen, S.C. van Buul-Offers. Differential patterns of insulin-like growth factor -I and - II mRNA expression in medulloblastoma. Neuropathol. Appl. Neurobiol. 30: 503-512 (2004).
  • De Boer, L., H.E. van Duyvenvoorde, E.C. Willemstein-van Hove, C.M. Hoogerbrugge, J. van Doorn, J.A. Maassen, M. Karperien, J.M. Wit. Mutations in the NSD1 gene in patients with Sotos syndrome associate with endocrine and paracrine alterations in the IGF-system. Eur. J. Endocrinol. 151:333-341 (2004).
  • Walenkamp M.J.E., M. Karperien, A.M. Pereira, Y. Hilhorst-Hofstee, J. van Doorn, J.W. Chen, S. Mohan, A. Denley, B.E. Forbes, H.A. van Duyvenvoorde, S.W. van Thiel, C.A. Sluimers, J.J. Bax, J.A.P.M. de Laat, M.B. Breuning, J.A. Romijn, J.M. Wit. Homozygous and heterozygous expression of a novel IGF-I mutation. J. Clin. Endocrinol. Metab. 90:2855-2864 (2005).
  • Rooman, R.P.A., L. Op De Beeck, M. Martin, J. van Doorn, S. Mohan, M.V.L. Du Caju. Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature. Eur. J. Endocrinol. 152:597-604 (2005).



Latest update: 16 November 2005

Disclaimer© 2006-2012 UMC Utrecht, Alle rechten voorbehouden